Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

Completed

Conditions studied: Central Nervous System Diseases, Central Nervous System Neoplasms

In brief

Safety and Efficacy Study in pediatric subjects \<2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice. Retrospective enrolment with a prospective blinded read.

Key facts

Study ID
NCT03750188
Run by
Bracco Diagnostics, Inc
People needed
125
Starts
2018-11-01
Expected to finish
2019-10-16
Last updated by the study team
2020-01-23

Who can join

Age: 0 and older, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.